The North America ATP Assays Market was valued at USD 420 Million in 2025 and is expected to reach USD 1,120 Million by 2035, expanding at a CAGR of 9.5% from 2024 to 2035. This growth is driven by an increase in the adoption of ATP assays in pharmaceutical, biotechnology, and food safety applications, along with advancements in assay technologies.
The economic impact of tariffs on "North America ATP Assays Market".
Market Growth Drivers
Rising Prevalence of Chronic Diseases: The increasing burden of chronic diseases, such as cancer and infectious diseases, in North America is driving demand for rapid and sensitive diagnostic tools. ATP assays provide a reliable method for evaluating cell viability and cytotoxicity, aiding in early diagnosis and effective treatment planning. Companies like Thermo Fisher Scientific have expanded their ATP assay product lines to cater to the growing clinical and research applications in oncology and infectious disease detection.
Stringent Food Safety Regulations: Intensifying regulations by the FDA and other agencies regarding food safety and quality assurance have fuelled the adoption of ATP assays in the food & beverage industry. ATP bioluminescence assays offer rapid contamination detection and monitoring, helping companies such as Hygiena improve compliance and reduce contamination risks, supporting safer processing environments.
Market Trends
Integration of ATP Assays in Automation Platforms: The trend towards high-throughput screening and automation in research labs and clinical diagnostics is fueling the adoption of ATP assay kits compatible with automated platforms. Companies like Promega Corporation are developing ATP assays designed for robotic liquid handling systems, enhancing reproducibility and scalability of assays in drug discovery and cell-based screening.
Growing Adoption in Environmental Monitoring: There is a growing trend of employing ATP assays for environmental water testing, wastewater management, and monitoring of surface cleanliness in public spaces. Neogen Corporation has expanded its ATP assay portfolio to cater to environmental microbiology, offering rapid solutions for water quality and environmental surveillance.
Market Opportunities
Emergence of Personalized Medicine: ATP assays enable precise cell-based analysis required for personalized medicine and targeted therapies. Companies like BioVision are leveraging this opportunity to develop custom ATP assay kits tailored for advanced patient-specific research.
Expansion in Point-of-Care Testing: ATP assay technology is being miniaturized for portable and rapid point-of-care diagnostic applications, offering significant opportunity for market expansion in remote and resource-limited settings.
North America ATP Assays Market Revenue (USD Million), 2020-2035
The chart illustrates a robust growth trajectory for the North America ATP Assays Market, with revenues rising from USD 260 Million in 2020 to an estimated USD 1,120 Million by 2035. The growth reflects increasing application in diagnostics, food safety, and environmental monitoring, alongside advancements in assay sensitivity and automation. Notably, post-2025, the market is projected to accelerate due to expanded adoption in clinical diagnostics and personalized medicine, offering significant revenue upside through 2035.
North America ATP Assays Market by Regional Share (%), 2025
The pie chart displays the regional distribution of the ATP Assays Market in North America for 2025. The United States dominates the market with a 73% share, attributed to its advanced research infrastructure and strong presence of leading assay technology companies. Canada follows with 17% market share, driven by growing investments in biotechnology. Mexico accounts for 6%, while other Central America and Caribbean regions collectively hold 4%. This distribution highlights the regional focus and opportunities for growth in less-penetrated markets within North America.
Recent Developments in North America ATP Assays Market
In March 2024, Thermo Fisher Scientific launched its new ATP Lite II Luminescence Assay System, designed to provide ultra-sensitive detection for cell viability and cytotoxicity studies. The product leverages an enhanced luciferase enzyme and optimized reagents for automated high-throughput platforms, facilitating faster and more reliable data in drug discovery applications.
In April 2024, Promega Corporation announced a strategic partnership with Beckman Coulter Life Sciences to integrate its CellTiter-Glo ATP assays with Beckman's automated liquid handling systems. This collaboration aims to deliver seamless workflow solutions for biotechnology and pharmaceutical laboratories, enhancing assay productivity and scalability.
In May 2024, Neogen Corporation introduced ATP Verify, a next-generation environmental monitoring tool leveraging ATP bioluminescence for rapid hygiene and contamination assessments in food processing plants. The system features cloud-based analytics and real-time reporting, targeting increased regulatory compliance and operational efficiency.
Press Releases